Scientist, Bacteriology, Microbial Antibodies and Technologies

AstraZeneca; Gaithersburg (MD); On-site; USD 85,000 - 125,000; Full time

Job summary

AstraZeneca in Gaithersburg, MD is seeking a Scientist, Bacteriology, Microbial Antibodies and Technologies to advance our research in infectious diseases and innovative antimicrobial platforms.

The role involves collaborating with global teams to translate discoveries into medicines, designing and executing experiments, and applying cutting-edge techniques in bacteriology and antibody engineering to drive science forward.

Job description

Scientist, Bacteriology, Microbial Antibodies and Technologies

At AstraZeneca our mission is to create an inclusive and equitable environment, where people feel they belong. Our ongoing commitment to inclusion and diversity means we’re future proofing our business. It allows us to push the boundaries of science and deliver life-changing medicines to more and more patients around the world.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.

Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.

We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world's leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing.

AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, visit www.astrazeneca.com.